National and Kapodistrian University of Athens
Πειραματικά μοντέλα ανοσοθεραπείας HER-2/neu θετικών όγκων
Abstract
dc:descriptionOverexpression of the HER-2/neu oncogene by a significant number of human carcinomas has been associated with more aggressive disease. Despite its high oncogenic potential, HER2/neu oncoprotein has been considered as a promising target for cancer therapeutics as it has been proven to be immunogenic in vivo inducing specific CTL and IgG responses in a considerable subset of patients with HER-2/neu positive breast cancer. Moreover, various MHC class I- and class II-binding peptides from the HER-2/neu sequence were also able to elicit in vitro tumor reactive CTL and T helper (Th) responses, respectively. However, synthetic peptides corresponding to HER-2/neu immunogenic epitopes have greatly failed to function as therapeutic vaccines in phase I/II trials. Due to the fact that HER-2/neu is a self-protein, tolerance mechanisms may provide a serious obstacle towards the development of efficient anti-tumor responses in vivo. In order to circumvent tolerance against the HER-2/neu protein, several approaches have been invented and applied in preclinical models, resulting in more persistent and efficient antitumor responses. However, in parallel with studies aiming at improving the effectiveness of a vaccine, it has been considered essential to identify novel immunogenic CTL epitopes, aiming at providing insight into the design of more efficacious peptide-based treatment modalities. This study describes a novel HLA-A*0201-restricted epitope, encompassing amino acids 828-836 (residues QIAKGMSYL), which is naturally presented by various HER-2/neu⁺ tumor cell lines. HER-2/neu(828-836), [HER-2(9₈₂₈)], possesses two anchor residues and stabilized HLA-A*0201 on T2 cells in a concentration-dependent class I binding assay. This peptide was stable for 3.5h in an off-kinetics assay. HER-2(9₈₂₈) was found to be immunogenic in HLAA*0201 transgenic (HHD) mice inducing peptide-specific and functionally potent CTL and lasting anti-tumor immunity. Most important, using HLA-A*0201 pentamer analysis we could detect increased ex vivo frequencies of CD8⁺ T lymphocytes specifically recognizing HER2(9₈₂₈) in eight out of twenty HLA-A*0201⁺ HER-2/neu⁺ breast cancer patients. Moreover, HER2(9₈₂₈)-specific human CTL recognized the tumor cell line SKOV3.A2 as well as the primary RS.A2.1.DR1 tumor cell line both expressing HER-2/neu and HLA-A*0201. Finally, therapeutic vaccination with HER-2(9₈₂₈) in HHD mice was proven effective against established transplantable ALC.A2.1.HER tumors, inducing complete tumor regression in 50% of mice. Our data encourage further exploitation of HER-2(9₈₂₈) as a promising candidate for peptide-based cancer vaccines. The necessity of CD4 T-cell help to generate and sustain MHC class I–restricted CD8 T-cell responses has led to the identification of a new MHC class II–restricted epitope derived from the human HER-2/neu protein, namely HER-2(15₈₂₂). This helper 15-mer peptide, which exhibits a very strong binding score with the HLA-DRB1*0101 (HLA-DR1) molecule (according to the SYFPEITHI database) encompasses the amino acid sequence of the cytotoxic epitope, HER2(9₈₂₈), which has been identified as a potent immunogenic peptide. By applying a vaccination protocol based on the administration of the HER-2(15₈₂₂) in the HLA-A2.1/HLA-DR1 mouse model, it was evident that this peptide was recognized not only by syngeneic splenocytes pulsed with the peptide but also by the primary cancer cell line RS.A2.1.DR1, which it has been shown to naturally express the HER-2(9₈₂₈). More importantly, therapeutic vaccination of the newly established HLA-A2.1/DR1 X neuT⁺ mouse model tolerant to rat neu and transgenic for HLAA*0201 and HLA-DRB1*0101 with the xenogeneic human HER-2(9₈₂₈) and HER-2(15₈₂₂) peptides has been found very successful. Vaccination with the HER-2(15₈₂₂) helper epitope (86% sequence homology with the rat peptide) induced a considerable delay of up to 8 weeks in spontaneous mammary tumor growth compared to the untreated mice (P=0.0001). Whereas vaccination of the same mice with the HER-2(9₈₂₈) cytotoxic peptide conferred a delay in tumor growth of a maximum 5 weeks compared to the untreated mice (P=0.0003). Based on the above findings one can conclude that HER-2(15₈₂₂) helper peptide is indeed immunogenic and capable of successfully enhancing the cytotoxic activity of HER-2(9₈₂₈) as seen in both in vitro and in vivo settings. In a supplementary study, by applying the same prediction algorithms for MHC class I ligands and proteosomal cleavages, we have been able to identify the HER-2/neu decamer LIAHNQVRQV spanning residues 85-94 [HER-2(10₈₅)]. HER-2(10₈₅) proved to bind with high affinity to HLA-A*0201 and was stable for 4 h in an off-kinetics assay. This peptide was immunogenic in HLA-A2.1 transgenic (HHD) mice inducing peptide-specific CTL, which responded to tumor cell lines of various origin co-expressing human HER-2/neu and HLAA*0201. This demonstrates that HER-2(10₈₅) is naturally processed from endogenous HER2/neu. Five of sixteen HER-2/neu + HLA-A*0201+ breast cancer patients analyzed, had HER2(10₈₅)-reactive T cells ranging from 0.35% to 0.70% of CD8⁺ T cells. Depletion of regulatory T (Treg) cells from PBMC enabled the rapid expansion of HLA-A*0201/HER2(1085)pentamer⁺/CD8⁺ cells (PENT⁺/CD8⁺), whereas significantly lower numbers of CTL could be generated from unfractionated PBMC. HER-2(1085)-specific human CTL recognized the HER-2/neu⁺ HLA-A*0201⁺ tumor cell line SKBR3.A2, as determined by IFN-γ intracellular staining and in the high-sensitivity CD107α degranulation assay. Finally, HER-2(10₈₅) significantly prolonged the survival of HHD mice inoculated with the transplantable ALC.A2.1.HER tumor both in prophylactic and therapeutic settings. These data demonstrate that HER-2(1085) is an immunogenic peptide, capable of eliciting CD8-mediated responses in vitro and in vivo, providing the platform for further exploitation of HER-2(10₈₅) as a possible target for anticancer immunotherapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lekka, Eftychia
- Λέκκα, Ευτυχία
Subjects
dc:subject × 14- Ογκοπρωτεΐνη HER/2-neu
- Πεπτιδικά εμβόλια
- Διαγονιδιακά πειραματόζωα
- Κυτταροτοξικά Τ λεμφοκύτταρα
- Καρκίνος μαστού
- HER-2/neu oncoprotein
- Peptide vaccines
- Transgenic mouse models
- Cytotoxic T lymphocytes
- Breast cancer
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23771